Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 65
Filter
1.
AJNR Am J Neuroradiol ; 40(11): 1804-1810, 2019 11.
Article in English | MEDLINE | ID: mdl-31694820

ABSTRACT

BACKGROUND AND PURPOSE: Diffuse midline gliomas with histone H3 K27M mutation are biologically aggressive tumors with poor prognosis defined as a new diagnostic entity in the 2016 World Health Organization Classification of Tumors of the Central Nervous System. There are no qualitative imaging differences (enhancement, border, or central necrosis) between histone H3 wildtype and H3 K27M-mutant diffuse midline gliomas. Herein, we evaluated the utility of diffusion-weighted imaging to distinguish H3 K27M-mutant from histone H3 wildtype diffuse midline gliomas. MATERIALS AND METHODS: We identified 31 pediatric patients (younger than 21 years of age) with diffuse gliomas centered in midline structures that had undergone assessment for histone H3 K27M mutation. We measured ADC within these tumors using a voxel-based 3D whole-tumor measurement method. RESULTS: Our cohort included 18 infratentorial and 13 supratentorial diffuse gliomas centered in midline structures. Twenty-three (74%) tumors carried H3-K27M mutations. There was no difference in ADC histogram parameters (mean, median, minimum, maximum, percentiles) between mutant and wild-type tumors. Subgroup analysis based on tumor location also did not identify a difference in histogram descriptive statistics. Patients who survived <1 year after diagnosis had lower median ADC (1.10 × 10-3mm2/s; 95% CI, 0.90-1.30) compared with patients who survived >1 year (1.46 × 10-3mm2/s; 95% CI, 1.19-1.67; P < .06). Average ADC values for diffuse midline gliomas were 1.28 × 10-3mm2/s (95% CI, 1.21-1.34) and 0.86 × 10-3mm2/s (95% CI, 0.69-1.01) for hemispheric glioblastomas with P < .05. CONCLUSIONS: Although no statistically significant difference in diffusion characteristics was found between H3-K27M mutant and H3 wildtype diffuse midline gliomas, lower diffusivity corresponds to a lower survival rate at 1 year after diagnosis. These findings can have an impact on the anticipated clinical course for this patient population and offer providers and families guidance on clinical outcomes.


Subject(s)
Brain Neoplasms/diagnostic imaging , Glioma/diagnostic imaging , Adolescent , Adult , Brain Neoplasms/genetics , Brain Neoplasms/pathology , Child , Cohort Studies , Diffusion Magnetic Resonance Imaging/methods , Female , Glioma/genetics , Glioma/pathology , Humans , Jumonji Domain-Containing Histone Demethylases/genetics , Male , Mutation , Young Adult
2.
AJNR Am J Neuroradiol ; 40(3): 433-439, 2019 03.
Article in English | MEDLINE | ID: mdl-30819773

ABSTRACT

BACKGROUND AND PURPOSE: Chordoid meningiomas are uncommon WHO grade II primary intracranial neoplasms that possess unique chordoid histology and follow an aggressive clinical course. Our aim was to assess the utility of qualitative MR imaging features and quantitative apparent diffusion coefficient values as distinguishing preoperative MR imaging metrics to identify and differentiate chordoid histology from other meningioma histologic subtypes. MATERIALS AND METHODS: Twenty-one patients with meningiomas with chordoid histology, which included both chordoid meningiomas (>50% chordoid histology) and meningiomas with focal chordoid histology (<50% chordoid histology) with available preoperative MR imaging examinations, including diffusion-weighted imaging, were identified. Qualitative imaging features and quantitative ADC values were compared between meningiomas with chordoid histology and 42 nonchordoid meningiomas (29 WHO grade I, eleven WHO grade II, and 2 WHO grade III). RESULTS: The median ADC (10-3mm2/s) of meningiomas with chordoid histology was significantly higher than nonchordoid meningiomas (1.16 versus 0.92, P < .001), as was the median normalized ADC (1.60 versus 1.19, P < .001). In subgroup analysis, the median and normalized ADC values of chordoid meningiomas (n = 11) were significantly higher than those in meningiomas with focal chordoid histology (n = 10, P < .001 and P < .001, respectively) or nonchordoid meningiomas (n = 42, P < .001 and <0.001, respectively). Median and normalized ADC values were not significantly different between the meningiomas with focal chordoid histology and nonchordoid meningiomas (P = .816 and .301, respectively). Among the qualitative imaging features, only DWI signal intensity was significantly associated with meningiomas with chordoid histology diagnosis. CONCLUSIONS: ADC values are higher in chordoid compared with nonchordoid meningiomas and may be used to discriminate the degree of chordoid histology in meningiomas. While qualitative MR imaging features do not strongly discriminate chordoid from nonchordoid meningiomas, DWI may allow preoperative identification of chordoid meningiomas.


Subject(s)
Meningeal Neoplasms/diagnostic imaging , Meningeal Neoplasms/pathology , Meningioma/diagnostic imaging , Meningioma/pathology , Neuroimaging/methods , Adult , Aged , Female , Humans , Image Interpretation, Computer-Assisted/methods , Magnetic Resonance Imaging/methods , Male , Middle Aged
3.
Neuropathol Appl Neurobiol ; 45(1): 58-80, 2019 02.
Article in English | MEDLINE | ID: mdl-30582188

ABSTRACT

Frontotemporal dementia (FTD) encompasses a collection of clinically and pathologically diverse neurological disorders. Clinical features of behavioural and language dysfunction are associated with neurodegeneration, predominantly of frontal and temporal cortices. Over the past decade, there have been significant advances in the understanding of the genetic aetiology and neuropathology of FTD which have led to the creation of various disease models to investigate the molecular pathways that contribute to disease pathogenesis. The generation of in vivo models of FTD involves either targeting genes with known disease-causative mutations such as GRN and C9orf72 or genes encoding proteins that form the inclusions that characterize the disease pathologically, such as TDP-43 and FUS. This review provides a comprehensive summary of the different in vivo model systems used to understand pathomechanisms in FTD, with a focus on disease models which reproduce aspects of the wide-ranging behavioural phenotypes seen in people with FTD. We discuss the emerging disease pathways that have emerged from these in vivo models and how this has shaped our understanding of disease mechanisms underpinning FTD. We also discuss the challenges of modelling the complex clinical symptoms shown by people with FTD, the confounding overlap with features of motor neuron disease, and the drive to make models more disease-relevant. In summary, in vivo models can replicate many pathological and behavioural aspects of clinical FTD, but robust and thorough investigations utilizing shared features and variability between disease models will improve the disease-relevance of findings and thus better inform therapeutic development.


Subject(s)
Disease Models, Animal , Frontotemporal Dementia/genetics , Frontotemporal Dementia/pathology , Frontotemporal Dementia/physiopathology , Animals , Humans
4.
AJNR Am J Neuroradiol ; 38(4): 795-800, 2017 Apr.
Article in English | MEDLINE | ID: mdl-28183840

ABSTRACT

BACKGROUND AND PURPOSE: The 2016 World Health Organization Classification of Tumors of the Central Nervous System includes "diffuse midline glioma with histone H3 K27M mutation" as a new diagnostic entity. We describe the MR imaging characteristics of this new tumor entity in pediatric patients. MATERIALS AND METHODS: We retrospectively reviewed imaging features of pediatric patients with midline gliomas with or without the histone H3 K27 mutation. We evaluated the imaging features of these tumors on the basis of location, enhancement pattern, and necrosis. RESULTS: Among 33 patients with diffuse midline gliomas, histone H3 K27M mutation was present in 24 patients (72.7%) and absent in 9 (27.3%). Of the tumors, 27.3% (n = 9) were located in the thalamus; 42.4% (n = 14), in the pons; 15% (n = 5), within the vermis/fourth ventricle; and 6% (n = 2), in the spinal cord. The radiographic features of diffuse midline gliomas with histone H3 K27M mutation were highly variable, ranging from expansile masses without enhancement or necrosis with large areas of surrounding infiltrative growth to peripherally enhancing masses with central necrosis with significant mass effect but little surrounding T2/FLAIR hyperintensity. When we compared diffuse midline gliomas on the basis of the presence or absence of histone H3 K27M mutation, there was no significant correlation between enhancement or border characteristics, infiltrative appearance, or presence of edema. CONCLUSIONS: We describe, for the first time, the MR imaging features of pediatric diffuse midline gliomas with histone H3 K27M mutation. Similar to the heterogeneous histologic features among these tumors, they also have a diverse imaging appearance without distinguishing features from histone H3 wildtype diffuse gliomas.


Subject(s)
Central Nervous System Neoplasms/diagnostic imaging , Central Nervous System Neoplasms/genetics , Glioma/diagnostic imaging , Glioma/genetics , Histones/genetics , Adolescent , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/genetics , Child , Child, Preschool , Cranial Fossa, Posterior/diagnostic imaging , Female , Humans , Image Processing, Computer-Assisted , Infant , Magnetic Resonance Imaging , Male , Mutation , Neuroimaging , Retrospective Studies , Spinal Cord Neoplasms/diagnostic imaging , Spinal Cord Neoplasms/genetics , Tectum Mesencephali/diagnostic imaging , Young Adult
5.
AJNR Am J Neuroradiol ; 36(7): 1349-54, 2015 Jul.
Article in English | MEDLINE | ID: mdl-25857757

ABSTRACT

Malignant gliomas are characterized by infiltrative growth of tumor cells, including along white matter tracts. This may result in clinical cranial neuropathy due to direct involvement of a cranial nerve rather than by leptomeningeal spread along cranial nerves. Gliomas directly involving cranial nerves III-XII are rare, with only 11 cases reported in the literature before 2014, including 8 with imaging. We present 8 additional cases demonstrating direct infiltration of a cranial nerve by a glioma. Asymmetric cisternal nerve expansion compared with the contralateral nerve was noted with a mean length of involvement of 9.4 mm. Based on our case series, the key imaging feature for recognizing direct cranial nerve involvement by a glioma is the detection of an intra-axial mass in the pons or midbrain that is directly associated with expansion, signal abnormality, and/or enhancement of the adjacent cranial nerves.


Subject(s)
Brain Neoplasms/pathology , Cranial Nerves/pathology , Glioma/pathology , Female , Humans , Male , Middle Aged
6.
Psychol Med ; 39(5): 763-71, 2009 May.
Article in English | MEDLINE | ID: mdl-18667100

ABSTRACT

BACKGROUND: Suicide is a leading cause of death and has been strongly associated with affective disorders. The influence of affective disorder polarity on subsequent suicide attempts or completions and any differential effect of suicide risk factors by polarity were assessed in a prospective cohort. METHOD: Participants with major affective disorders in the National Institute of Mental Health (NIMH) Collaborative Depression Study (CDS) were followed prospectively for up to 25 years. A total of 909 participants meeting prospective diagnostic criteria for major depressive and bipolar disorders were followed through 4204 mood cycles. Suicidal behavior was defined as suicide attempts or completions. Mixed-effects, grouped-time survival analysis assessed risk of suicidal behavior and differential effects of risk factors for suicidal behavior by polarity. In addition to polarity, the main effects of age, gender, hopelessness, married status, prior suicide attempts and active substance abuse were modeled, with mood cycle as the unit of analysis. RESULTS: After controlling for age of onset, there were no differences in prior suicide attempts by polarity although bipolar participants had more prior severe attempts. During follow-up, 40 cycles ended in suicide and 384 cycles contained at least one suicide attempt. Age, hopelessness and active substance abuse but not polarity predicted suicidal behavior. The effects of risk factors did not differ by polarity. CONCLUSIONS: Bipolarity does not independently influence risk of suicidal behavior or alter the influence of well-established suicide risk factors within affective disorders. Suicide risk assessment strategies may continue to appraise these common risk factors without regard to mood polarity.


Subject(s)
Bipolar Disorder/mortality , Depressive Disorder, Major/mortality , Suicide, Attempted/statistics & numerical data , Suicide/statistics & numerical data , Adult , Cohort Studies , Comorbidity , Cost of Illness , Depressive Disorder, Major/psychology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Personality Inventory/statistics & numerical data , Prospective Studies , Psychometrics , Risk Factors , Socioeconomic Factors , Substance-Related Disorders/mortality , Substance-Related Disorders/psychology , Suicide/psychology , Suicide, Attempted/psychology , Survival Analysis , United States , Young Adult
7.
Stat Med ; 20(9-10): 1487-98, 2001.
Article in English | MEDLINE | ID: mdl-11343369

ABSTRACT

The propensity score adjustment is a method to reduce bias in observational studies. We propose a strategy that involves a novel combination of three data analytic techniques, which adapts the propensity adjustment for additional perturbations of longitudinal, observational studies. First, ordinal logistic regression examines propensity for ordinal doses of treatment. Second, a mixed-model approach incorporates the multiple treatment trials and multiple episodes that are characteristic of chronically ill subjects. Finally, a mixed-effects grouped-time survival model incorporates the propensity score in treatment effectiveness analyses. The strategy that is applied here to an observational study of affective illness can also be used to evaluate the effectiveness of treatments for other chronic illnesses.


Subject(s)
Logistic Models , Treatment Outcome , Adolescent , Adult , Antidepressive Agents/administration & dosage , Antidepressive Agents/therapeutic use , Data Interpretation, Statistical , Depression/drug therapy , Humans , Longitudinal Studies , Multicenter Studies as Topic , Observer Variation , Randomized Controlled Trials as Topic , Survival Analysis
8.
Psychiatr Serv ; 52(2): 229-31, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11157124

ABSTRACT

OBJECTIVE: Although psychiatrists in the United States have used lithium for nearly 30 years, toxicity still occurs frequently. The authors report an attempt to reduce the incidence of lithium toxicity in hospitalized psychiatric patients and to identify factors associated with toxicity. METHODS: Serum lithium levels were monitored by the drug use evaluation committee at a psychiatric hospital between 1990 and 1996. Each laboratory result showing a serum lithium level of 1.5 mmol/L or more was promptly investigated, and the results were reported quarterly to the hospital staff association. RESULTS: The study found that in 6.8 percent of the 2,210 admissions during which lithium was administered, patients had serum levels of 1.5 mmol/L or higher. The number of excessive serum lithium levels decreased over the course of the study period. Only 27.8 percent of patients with excessive levels had signs and symptoms of toxicity. Of the excessive serum lithium levels that were investigated, 43.3 percent were detected in blood samples drawn at the time of admission. Women and elderly persons were significantly more likely to have excessive serum levels. Psychiatric diagnosis was not significantly associated with excessive serum levels. CONCLUSIONS: Education by the drug use evaluation committee may have helped to reduce the number of patients who experienced excessive lithium levels while hospitalized. Vigilance should be emphasized for women and elderly persons.


Subject(s)
Bipolar Disorder/blood , Depressive Disorder, Major/blood , Lithium Carbonate/adverse effects , Psychotic Disorders/blood , Adolescent , Adult , Aged , Bipolar Disorder/drug therapy , Depressive Disorder, Major/drug therapy , Dose-Response Relationship, Drug , Drug Monitoring , Female , Hospitalization , Humans , Lithium Carbonate/administration & dosage , Lithium Carbonate/blood , Male , Metabolic Clearance Rate , Middle Aged , Psychotic Disorders/drug therapy , Risk Factors
9.
Am J Psychiatry ; 157(9): 1501-4, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10964869

ABSTRACT

OBJECTIVE: This study investigated the influence of incomplete recovery from first lifetime major depressive episodes on long-term outcome. METHOD: After their first lifetime major depressive episode, patients were divided into asymptomatic (N=70) and residual subthreshold depressive symptom (N=26) recovery groups and compared on longitudinal course during up to 12 years of prospective naturalistic follow-up. RESULTS: Patients with residual subthreshold depressive symptoms during recovery had significantly more severe and chronic future courses. Those with residual symptoms relapsed to major and minor depressive episodes faster and had more recurrences, shorter well intervals, and fewer symptom-free weeks during follow-up than asymptomatic patients. CONCLUSIONS: Resolution of major depressive episodes with residual subthreshold depressive symptoms, even the first lifetime episode, appears to be the first step of a more severe, relapsing, and chronic future course. When ongoing subthreshold symptoms continue after major depressive episodes, the illness is still active, and continued treatment is strongly recommended.


Subject(s)
Depressive Disorder/diagnosis , Antidepressive Agents/therapeutic use , Chronic Disease , Comorbidity , Depressive Disorder/drug therapy , Depressive Disorder/psychology , Dysthymic Disorder/diagnosis , Dysthymic Disorder/psychology , Follow-Up Studies , Hospitalization , Humans , Longitudinal Studies , Outcome Assessment, Health Care , Prospective Studies , Recurrence , Severity of Illness Index , Survival Analysis
10.
Am J Psychiatry ; 157(2): 229-33, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10671391

ABSTRACT

OBJECTIVE: The authors of this study examined multiple recurrences of unipolar major depressive disorder. METHOD: A total of 318 subjects with unipolar major depressive disorder were prospectively followed for 10 years within a multicenter naturalistic study. Survival analytic techniques were used to examine the probability of recurrence after recovery from the index episode. RESULTS: The mean number of episodes of major depression per year of follow-up was 0. 21, and nearly two-thirds of the subjects suffered at least one recurrence. The number of lifetime episodes of major depression was significantly associated with the probability of recurrence, such that the risk of recurrence increased by 16% with each successive recurrence. The risk of recurrence progressively decreased as the duration of recovery increased. Within subjects, there was very little consistency in the time to recurrence. CONCLUSIONS: Major depressive disorder is a highly recurrent illness. The risk of the recurrence of major depressive disorder progressively increases with each successive episode and decreases as the duration of recovery increases.


Subject(s)
Depressive Disorder/diagnosis , Adolescent , Adult , Aged , Antidepressive Agents/therapeutic use , Cohort Studies , Depressive Disorder/psychology , Depressive Disorder/therapy , Electroconvulsive Therapy , Female , Follow-Up Studies , Humans , Lithium/therapeutic use , Male , Middle Aged , Probability , Prospective Studies , Recurrence , Risk Factors , Survival Analysis
11.
J Nerv Ment Dis ; 188(12): 805-12, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11191580

ABSTRACT

Those afflicted with bipolar disorder often suffer from substantial functional impairment both when in episode and when in remission. This study examined the psychometric properties of a brief assessment of psychosocial functioning, the Range of Impaired Functioning Tool (LIFE-RIFT), among subjects with bipolar I disorder. The study sample consisted of 163 subjects who presented with bipolar I disorder at intake into the NIMH Collaborative Depression Study (CDS). All LIFE-RIFT items come from the Longitudinal Interval Follow-up Evaluation (LIFE). Follow-up data that were used to examine the reliability and validity of the scale come from assessments of psychosocial functioning that were conducted 6, 12, 18, and 24 months after intake into the CDS. The results of factor analyses indicate that the scale items are measures of one construct, psychosocial functioning. The interrater agreement on the scale score was very good with an intraclass correlation coefficient was 0.94. The internal consistency reliability among the scale items was uniformly satisfactory over the four assessment periods, with coefficient alpha ranging from 0.78 to 0.84. Mixed-effect regression analyses showed that during mood episodes subjects were significantly more impaired than those in recovery. In conclusion, the psychometric properties of the LIFE-RIFT were examined in subjects with bipolar I disorder. The analyses from this longitudinal, observational study provide empirical support for the reliability and validity of the scale. The LIFE-RIFT provides a brief, inexpensive alternative to scales currently used to assess psychosocial functioning and can be easily added to semistructured assessments that are used in clinical and treatment outcome studies.


Subject(s)
Adaptation, Psychological , Bipolar Disorder/diagnosis , Psychiatric Status Rating Scales/statistics & numerical data , Social Adjustment , Adult , Bipolar Disorder/psychology , Factor Analysis, Statistical , Female , Follow-Up Studies , Humans , Longitudinal Studies , Male , Outcome Assessment, Health Care , Psychometrics , Reproducibility of Results
13.
Psychol Med ; 29(4): 869-78, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10473314

ABSTRACT

BACKGROUND: The literature documents that functional impairment is associated with affective disorders. Nevertheless, the choice among thorough, yet brief, well-validated assessments of functional impairment is limited. The objective of this study was to evaluate the psychometric properties of a brief scale of functional impairment, the Range of Impaired Functioning Tool (LIFE-RIFT). METHOD: The study sample included subjects who presented with major depressive disorder at intake into the NIMH Collaborative Depression Study (CDS). The LIFE-RIFT is composed of items that are included in the Longitudinal Interval Follow-up Evaluation (LIFE). The reliability and validity were examined using data from LIFE-RIFT assessments conducted at four points in time: 6, 12, 18 and 24 months after intake into the CDS. RESULTS: Cross-sectional one factor models accounted for the covariance structure among the four scale items. A longitudinal factor model, with an invariant factor structure over time, also fitted the data well and indicated that the scale items are measures of one construct, namely functional impairment. The internal consistency reliability of the scale was supported with alpha coefficients ranging from 0.81 to 0.83. The inter-rater reliability intraclass correlation coefficient (ICC) was 0.94. Mixed-effect linear regression models showed that those in episode were significantly more impaired than those in recovery. Furthermore, in analyses of predictive validity, impairment was positively associated with subsequent recurrence and negatively associated with subsequent recovery. CONCLUSIONS: This psychometric evaluation provides empirical support for the reliability and validity of the LIFE-RIFT, a brief measure of functional impairment.


Subject(s)
Activities of Daily Living/psychology , Depressive Disorder, Major/diagnosis , Activities of Daily Living/classification , Adult , Depressive Disorder, Major/psychology , Female , Follow-Up Studies , Humans , Longitudinal Studies , Male , Middle Aged , Personality Assessment/statistics & numerical data , Psychometrics
14.
Am J Psychiatry ; 156(7): 1000-6, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10401442

ABSTRACT

OBJECTIVE: The recurrence of an affective disorder in people who initially recover from major depressive disorder was characterized by using the unique longitudinal prospective follow-up data from the National Institute of Mental Health Collaborative Program on the Psychobiology of Depression-Clinical Studies. METHOD: Up to 15 years of prospective follow-up data on the course of major depressive disorder were available for 380 subjects who recovered from an index episode of major depressive disorder and for 105 subjects who subsequently remained well for at least 5 years after recovery. Baseline demographic and clinical characteristics were examined as predictors of recurrence of an affective disorder. The authors also examined naturalistically applied antidepressant therapy. RESULTS: A cumulative proportion of 85% (Kaplan-Meier estimate) of the 380 recovered subjects experienced a recurrence, as did 58% (Kaplan-Meier estimate) of those who remained well for at least 5 years. Female sex, a longer depressive episode before intake, more prior episodes, and never marrying were significant predictors of a recurrence. None of these or any other characteristic persisted as a predictor of recurrence in subjects who recovered and were subsequently well for at least 5 years. Subjects reported receiving low levels of antidepressant treatment during the index episode, which further decreased in amount and extent during the well interval. CONCLUSIONS: Few baseline demographic or clinical characteristics predict who will or will not experience a recurrence of an affective disorder after recovery from an index episode of major depressive disorder, even in persons with lengthy well intervals. Naturalistically applied levels of antidepressant treatment are well below those shown effective in maintenance pharmacotherapy studies.


Subject(s)
Antidepressive Agents/therapeutic use , Depressive Disorder/therapy , Adult , Combined Modality Therapy , Depressive Disorder/diagnosis , Depressive Disorder/drug therapy , Electroconvulsive Therapy , Female , Follow-Up Studies , Humans , Imipramine/therapeutic use , Longitudinal Studies , Male , National Institute of Mental Health (U.S.) , Prognosis , Proportional Hazards Models , Prospective Studies , Psychiatric Status Rating Scales/statistics & numerical data , Recurrence , Survival Analysis , Treatment Outcome , United States
15.
Chest ; 115(4): 1092-5, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10208213

ABSTRACT

INTRODUCTION: Modern low-pressure, high-volume cuffed tracheotomy tubes have been shown to decrease tracheal injury. However, injury still occurs in patients requiring prolonged mechanical ventilation and prevents weaning, delays decannulation, prolongs hospitalization, and may totally obstruct the airway. We describe 37 patients, including the first reported case of failure to wean due to tracheal obstruction. METHODS: Over a 3-year period, from September 1994 to August 1997, the hospital records of 37 patients requiring prolonged mechanical ventilation (> 4 weeks) and found to have tracheal obstruction were reviewed retrospectively. They were a subgroup of 756 patients admitted to hospitals during the same period. The average endotracheal/tracheostomy cannulation time was 3 weeks/12 weeks (range 2 to 4 weeks/8 to 14 weeks). Average age was 76 years (range, 34 to 81). Underlying diseases included COPD, postcoronary artery bypass graft surgery, postpneumonectomy, severe pneumonia, acute lung injury, and ischemic heart disease. RESULTS: All 37 patients who initially failed to wean had difficulty in breathing and developed intermittent high peak airway pressures either early or during the weaning process or just on being ventilated. The insertion of a longer tracheal tube bypassed the obstruction, reestablished the airway, decreased peak airway pressures, and allowed the patient to breathe more easily. The obstruction was confirmed on bronchoscopy. Treatment consisted of either placement of a longer tracheal tube (34 of 37 patients) or placement of a tracheal stent. All but two of the patients (5.4%) were able to be weaned within a week. The two patients who still failed to be weaned were subsequently diagnosed as having amyotrophic lateral sclerosis. CONCLUSION: Tracheal obstruction in patients requiring prolonged mechanical ventilation prevented weaning. Reestablishment of the airway with a longer tracheal tube or tracheal stent allowed most of the patients to be weaned.


Subject(s)
Intubation, Intratracheal/adverse effects , Respiration, Artificial/adverse effects , Tracheal Stenosis/etiology , Ventilator Weaning , Adult , Aged , Aged, 80 and over , Bronchoscopy , Female , Humans , Intubation, Intratracheal/instrumentation , Male , Middle Aged , Retrospective Studies , Time Factors , Tracheal Stenosis/diagnosis , Tracheal Stenosis/therapy
16.
J Nerv Ment Dis ; 187(3): 181-7, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10086475

ABSTRACT

Five independent studies show that polarity sequence is associated with prognosis in bipolar I disorder. Episodes in which major depression precedes mania (DMI) lead to higher morbidity than biphasic episodes which begin with mania (MDI). However, little is known about the prognostic significance of polarity sequence for long-term outcome. This study examined polarity sequence across multiple episodes among 165 bipolar I patients followed prospectively for up to 15 years as part of the NIMH Collaborative Study of Depression. Episodes beginning with major depression were significantly longer than those beginning with mania for the first three prospectively observed episodes when pooling all episode types-monophasic, biphasic, and polyphasic. Furthermore, affective polarity at onset for the first prospectively observed episode was associated with polarity at onset for the remaining three episodes. Patients whose first prospectively observed episode began with depression had higher overall morbidity during the entire follow-up period.


Subject(s)
Bipolar Disorder/diagnosis , Adult , Antidepressive Agents/therapeutic use , Bipolar Disorder/drug therapy , Bipolar Disorder/psychology , Comorbidity , Depressive Disorder/diagnosis , Depressive Disorder/drug therapy , Depressive Disorder/psychology , Female , Follow-Up Studies , Humans , Lithium/therapeutic use , Male , National Institute of Mental Health (U.S.) , Outcome Assessment, Health Care , Prognosis , Prospective Studies , Psychiatric Status Rating Scales/statistics & numerical data , Recurrence , United States
17.
Acta Psychiatr Scand ; 99(2): 110-9, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10082186

ABSTRACT

This study examined the contribution of demographic, syndromal and longitudinal course variables to the long-term prognosis of 165 bipolar patients prospectively observed over 10 years as part of the National Institute of Mental Health Collaborative Study of Depression. Although most baseline clinical and demographic variables were not strong prognostic indicators, switching polarity within episodes was. Most episodes among the poor-prognosis patients were polyphasic, while most episodes among the comparison group with a better prognosis were monophasic. There was no evidence of shortening of cycle lengths over follow-up for either the poor-prognosis group or the entire sample. The relevance of these findings to the 'kindling' model is discussed.


Subject(s)
Bipolar Disorder/diagnosis , Adult , Bipolar Disorder/psychology , Female , Follow-Up Studies , Humans , Male , Predictive Value of Tests , Prognosis , Psychiatric Status Rating Scales , Time Factors
18.
Am J Psychiatry ; 156(2): 195-201, 1999 Feb.
Article in English | MEDLINE | ID: mdl-9989554

ABSTRACT

OBJECTIVE: There has been speculation in the literature about a link between fluoxetine use and suicidal behavior. The authors of this study hypothesized that there is no elevation in risk of suicidal behavior associated with use of fluoxetine. METHOD: The data come from the National Institute of Mental Health Collaborative Depression Study, a prospective, naturalistic follow-up of persons who presented for treatment of affective disorders. The analyses included data on 643 subjects who were followed up after fluoxetine was approved by the Food and Drug Administration in December 1987 for the treatment of depression. RESULTS: Nearly 30% (N = 185) of the study group was treated with fluoxetine at some point during the follow-up period. Relative to the other subjects, those who were subsequently treated with fluoxetine had onset of affective illness at a younger age and, after intake into the study and before 1988, had elevated rates of suicide attempts before fluoxetine treatment. A mixed-effects survival analysis that incorporated treatment exposure time, multiple treatment trials, and multiple suicide attempts per subject showed that relative to no treatment, use of fluoxetine and use of other somatic antidepressants were associated with nonsignificant reductions in the likelihood of suicide attempts or completions. Severity of psychopathology was strongly associated with elevated risk, and each suicide attempt after intake into the Collaborative Depression Study was associated with a marginally significant increase in risk of suicidal behavior. CONCLUSIONS: The results do not support the speculation that fluoxetine increases the risk of suicide. Rather, there was a nonsignificant reduction in risk of suicidal behavior among patients treated with fluoxetine, even though those subjects were more severely ill before treatment with fluoxetine.


Subject(s)
Depressive Disorder/drug therapy , Fluoxetine/therapeutic use , Selective Serotonin Reuptake Inhibitors/therapeutic use , Suicide/statistics & numerical data , Adult , Age of Onset , Antidepressive Agents/administration & dosage , Antidepressive Agents/adverse effects , Antidepressive Agents/therapeutic use , Depressive Disorder/psychology , Drug Administration Schedule , Female , Fluoxetine/administration & dosage , Fluoxetine/adverse effects , Follow-Up Studies , Humans , Male , Prospective Studies , Risk Factors , Selective Serotonin Reuptake Inhibitors/administration & dosage , Selective Serotonin Reuptake Inhibitors/adverse effects , Severity of Illness Index , Suicide/psychology , Suicide, Attempted/psychology , Suicide, Attempted/statistics & numerical data , Survival Analysis , Treatment Outcome
19.
J Clin Psychopharmacol ; 18(1): 38-49, 1998 Feb.
Article in English | MEDLINE | ID: mdl-9472841

ABSTRACT

Standard pharmacotherapy for the maintenance treatment of patients with bipolar I disorder consists of lithium, valproate, or carbamazepine. However, many patients fail to respond to monotherapy with any of these agents, and as a result, psychiatrists often resort to polypharmacy. Findings from some open-label trials and retrospective chart reviews suggest this approach may be useful, but in the few controlled trials that have been conducted, the results have been negative. One drug combination that warrants further study as maintenance therapy is lithium plus valproate. Each is approved by the U.S. Food and Drug Administration for treatment of acute mania, and lithium has demonstrated efficacy for maintenance treatment as well. Some preliminary evidence suggests that the combination can be effective for patients who do not respond to monotherapy, and it seems to be no more dangerous than monotherapy. Concomitant administration of lithium plus valproate does not significantly alter lithium pharmacokinetics, and statistically significant changes that arise in valproate pharmacokinetics are not clinically significant. Although it is not known whether the drugs interact to augment response, many of their effects in the central nervous system do differ, and there is no indication of pharmacodynamic interactions that oppose each other. Finally, some evidence suggests that lithium and valproate may differ with regard to clinical variables that predict response to treatment.


Subject(s)
Antidepressive Agents/therapeutic use , Antimanic Agents/therapeutic use , Bipolar Disorder/drug therapy , Lithium Carbonate/therapeutic use , Valproic Acid/therapeutic use , Clinical Trials as Topic , Drug Therapy, Combination , Humans , Lithium Carbonate/administration & dosage , Valproic Acid/administration & dosage
20.
Arch Gen Psychiatry ; 54(11): 1001-6, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9366656

ABSTRACT

BACKGROUND: Major depressive disorder is often marked by repeated episodes of depression. We describe recovery from major depression across multiple mood episodes in patients with unipolar major depression at intake and examine the association of sociodemographic and clinical variables with duration of illness. METHODS: A cohort of 258 subjects treated for unipolar major depressive disorder was followed up prospectively for 10 years as part of the Collaborative Depression Study, a multicenter naturalistic study of the mood disorders. Diagnoses were made according to the Research Diagnostic Criteria, and the course of illness was assessed with the Longitudinal Interval Follow-up Evaluation. Survival analyses were used to calculate the duration of illness for the first 5 recurrent mood episodes after recovery from the index episode. RESULTS: Diagnosis remained unipolar major depressive disorder for 235 subjects (91%). The median duration of illness was 22 weeks for the first recurrent mood episode, 20 weeks for the second, 21 weeks for the third, and 19 weeks for the fourth and fifth recurrent mood episodes; the 95% confidence intervals were highly consistent. From one episode to the next, the proportion of subjects who recovered by any one time point was similar. For subjects with 2 or more recoveries, the consistency of duration of illness from one recovery to the next was low to moderate. None of the sociodemographic or clinical variables consistently predicted duration of illness. CONCLUSION: In this sample of patients treated at tertiary care centers for major depressive disorder, the duration of recurrent mood episodes was relatively uniform and averaged approximately 20 weeks.


Subject(s)
Depressive Disorder/diagnosis , Adult , Combined Modality Therapy , Depressive Disorder/psychology , Depressive Disorder/therapy , Female , Follow-Up Studies , Humans , Imipramine/therapeutic use , Male , Marital Status , Prospective Studies , Psychiatric Status Rating Scales/statistics & numerical data , Psychotherapy , Recurrence , Severity of Illness Index , Social Class , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...